$ARDS News
Last published 3y ago
- 3y agoARDSAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateGlobeNewswireReceived two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis
- 3y agoARDSAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301GlobeNewswireLOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed single confirmatory
- 3y agoARDSAridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) DesignationGlobeNewswireQIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery
- 3y agoARDSRVSNAridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)ACCESS NewswireORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. and Rail Vision Ltd. on The RedChip Money Report® on Bloomberg TV, this
- 3y agoARDSAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)GlobeNewswireLPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the
- 3y agoARDSAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateGlobeNewswireLOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating
- 3y agoARDSAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignGlobeNewswireLOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced positive feedback from the FDA on the Company's proposed single confirmatory Phase 3 study of
- 3y agoARDSAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QGlobeNewswireLOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, announced today that it received a notice (the "Notice") from the
- 3y agoARDSAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KGlobeNewswireLOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, announced today that it received a notice (the "Notice") from
- 3y agoARDSAridis Provides Corporate UpdateGlobeNewswireLOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. The
- 3y agoARDSAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockGlobeNewswireLos Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale
- 3y agoARDSAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsGlobeNewswireThe study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif., March 13, 2023 (GLOBE
- 3y agoARDSDGLYRVSNInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R)ACCESS NewswireORLANDO, FL / ACCESSWIRE / February 17, 2023 / RedChip Companies will air new interviews with Rail Vision Ltd. , Aridis Pharmaceuticals, Inc. , and Digital Ally, Inc. on The
- 3y agoARDSAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)GlobeNewswireLOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of
- 3y agoARDSNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateGlobeNewswireAR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) --
- 3y agoARDSAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25GlobeNewswireLos Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat
- 3y agoARDS(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis FoundationGlobeNewswireLos Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock
- 3y agoARDSAridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis FoundationGlobeNewswireLos Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock
- 3y agoARDSAridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp BiopharmaceuticalGlobeNewswireThe Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif., Dec. 05, 2022
- 3y agoARDSAridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis PatientsGlobeNewswireLos Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating
- 3y agoARDSAridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious DiseasesGlobeNewswireThe Company's superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE)
- 3y agoARDSAridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business UpdateGlobeNewswireTop-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc.
- 4y agoARDSAridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority StudyPR NewswireOn track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif., Oct. 4, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) announced today that patient enrollment is clos
- 4y agoARDSAridis Pharmaceuticals Announces Withdrawal of Public Offering of Common StockPR NewswireLOS GATOS, Calif., Sept. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced tha
- 4y agoARDSAridis Pharmaceuticals Announces Proposed Public Offering of Common StockPR NewswireLOS GATOS, Calif., Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced tha
- 4y agoARDSAridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business UpdatePR NewswireMultiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective th
- 4y agoARDSAridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human PrimatesPR NewswireAR-701 is effective in vitro against SARS-CoV-2 Omicron subvariants, including BA.4 and BA.5 LOS GATOS, Calif., Aug. 10, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and developm
- 4y agoARDSAridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7PR NewswireLOS GATOS, Calif., June 3, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that
- 4y agoARDSAridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business UpdatePR NewswireMultiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective the
- 4y agoARDSAridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business UpdatePR NewswireAwarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals,
- 4y agoARDSAridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected AnimalsPR NewswireLOS GATOS, Calif., Feb. 17, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that
- 4y agoARDSBTUINVAMQ+1Thinking about buying stock in Marqeta, Innoviva, Seanergy Maritime, Peabody Energy, or Aridis Pharmaceuticals?PR NewswireNEW YORK, Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, INVA, SHIP, BTU, and ARDS. To
- 4y agoARDSCLNEGLPGMAT+1Thinking about buying stock in Aridis Pharmaceuticals, Galapagos, Qualtrics, Clean Energy Fuels, or Mattel?PR NewswireNEW YORK, Jan. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDS, GLPG, XM, CLNE, and MAT. To
- 4y agoARDSAridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 TransmissionPR NewswireLOS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, received a grant aw
- 4y agoARDSBVXVKPRXNAKD+1Thinking about buying stock in Reliance Global, Naked Brand, Kiora Pharmaceuticals, Aridis Pharmaceuticals, or Biondvax Pharmaceuticals?PR NewswireNEW YORK, Dec. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RELI, NAKD, KPRX, ARDS, and BVXV.
- 4y agoARDSAVCTGNCALICY+1Thinking about buying stock in Microbot Medical, Genocea Biosciences, Li-Cycle Holdings, American Virtual Cloud Technologies, or Aridis Pharmaceuticals?PR NewswireNEW YORK, Dec. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBOT, GNCA, LICY, AVCT, and ARDS.
- 4y agoARDSAridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business InterviewPR NewswireLOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today tha
- 4y agoARDSBFRIERJQNRX+1Thinking about buying stock in Quoin Pharmaceuticals, Aridis Pharmaceuticals, Biofrontera, Cassava Sciences, or Embraer SA?PR NewswireNEW YORK, Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QNRX, ARDS, BFRI, SAVA, and ERJ. T
- 4y agoARDSAridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human CoronavirusesPR NewswireLOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today tha
- 5y agoARDSAridis Pharmaceuticals Announces Third Quarter 2021 ResultsPR NewswireLOS GATOS, Calif., Nov. 10, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported fin
- 5y agoARDSAridis Pharmaceuticals Announces Second Quarter 2021 ResultsPR NewswireLOS GATOS, Calif., Aug. 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported finan
- 5y agoARDSAridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to MarketPR NewswireLOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that
- 5y agoARDSAridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)PR NewswireLOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today tha
- 5y agoARDSAZNAridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZenecaPR NewswireLOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (NASDAQ:AZN) to in-license the late stage monoclonal antibod
- 5y agoARDSAridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta VariantPR NewswireLOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that
- 5y agoARDSAridis Pharmaceuticals Announces First Quarter 2021 ResultsPR NewswireLOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported finan
- 5y agoARDSKermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)Business WireWhile there is currently no regulatory-approved vaccine or therapeutic antibody to combat the risks posed by ASFV to global pig livestock and food security, Kermode has been working to solve these challenges since the 2018 outbreak. Kermode Biotechn
- 5y agoARDSAridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business UpdatePR NewswireAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
- 5y agoARDSAridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®PR NewswireAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
- 5y agoARDSAridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with KermodePR NewswireAridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode...